Market Research Report
Global Tuberculosis Drug Market - 2019-2026
|Published by||DataM Intelligence||Product code||803292|
|Published||Content info||130-180 Pages
Delivery time: 1-2 business days
|Global Tuberculosis Drug Market - 2019-2026|
|Published: February 1, 2019||Content info: 130-180 Pages||
The Global Tuberculosis Drug market is expected to grow at a CAGR of XX% to reach a market value of USD XX million by 2026.
Tuberculosis (TB), known as poor man's disease, is caused by Mycobacterium tuberculosis germs that are spread from person to person through the air. TB usually affects the lungs and affects the other parts of the body such as the brain, the kidneys, or the spine. Across the globe, almost two billion people are infected with M. tuberculosis. In 2015, about 10.4 million new incidents of TB cases were reported worldwide, of which 6.01 million (50%-55%) were men, 3.6 million (30%-35%) were women, and one million (5%-10%) were children. According to research studies, in 2015 there were approximately 1.4 million people died due to TB, and an additional 400,000 people died due to infection of TB and human immunodeficiency virus (HIV) together. Around 60% of the new cases are reported in six countries namely India, China, Indonesia, Nigeria, Pakistan, and South Africa.
The major factors driving the global tuberculosis drug market are increasing incidence of TB in Africa and Asia, Emergence of MDR-TB and XDR-TB strains and Increase in outbreak of TB-HIV co-infections.
The World Health Organization (WHO) the incidence rates in Asia and Africa are high when compared with the America and Europe. The incidence rates are high due to lack of infrastructure, poor healthcare facilities, socioeconomic, untapped markets, and behavioral issues in these areas.
Africa has the highest incidence and prevalence rates of TB compared with any other region in the world, with more than three million new TB cases each year. Africa accounts for almost one-third of the global TB population. Moreover, 13 out of 15 countries with the highest TB incidence rates in the world exist in Africa, and nine out of 22 HBCs exist in Africa. Southeast Asia is the second most affected region in the world with 3.2 million new TB cases each year. Five out of 22 HBCs exist in Southeast Asia. In 2015, about 40% of the Indian population were infected with TB bacteria, the majority of them have latent TB. The levels of MDR-TB among newly infected TB patients are increasing in Asia and Africa. The high prevalence of TB in Asia and Africa is driving the global TB drug market.
The major effected TB countries among 30 WHO countries are Cambodia, India, and Indonesia, due to high prevalence and mortality rate with lower human development index, low gross domestic product, low per capita, and low intake of food supplements.
By drug type, the global tuberculosis drug market is segmented into first line drugs therapy, second line drugs therapy and combination drugs therapy. First line drug therapy segment holds the most significant share in 2018, owing to usage of combination of first-line drugs, around 90% of individuals with drug susceptible TB can be cured. Any delay and discontinuity during this treatment can lead to treatment failure and the emergence of drug resistance. The first-line anti-TB regimen comprises daily dosage of isoniazid, rifampicin, pyrazinamide, and ethambutol for two months, followed by a daily dosage of isoniazid and rifampicin for four months. The global first-line anti-TB drugs market is quite mature, and it is primarily dominated by generic medicines, and therefore, high volumes and low prices are the key features of this market.
The second-line anti-TB drugs are used to treat disease, which is resistant to first-line Therapy. The second-line anti-TB drugs are used in the treatment of MDR-TB when the treatment does not respond even to isoniazid and rifampicin, the most powerful anti-TB drugs. The drugs used in the treatment of MDR-TB or XDR-TB include levofloxacin, moxifloxacin and aminoglycosides (kanamycin and amikacin). In contrast to the global first-line anti-TB drugs market, this market is dominated by low volumes and high prices. The high prices for a quality-assured regimen make second-line anti-TB drugs almost unaffordable in developing nations. Lack of easy access to diagnostics, low priority in national treatment programs, and high costs of treatment are some of the chief features of this market.
The growing incidence rate of TB in the Americas in the recent times is expected to drive the adoption rates of TB drugs in the Americas. According to the CDC, 157 more cases of TB were reported in 2015 in the US compared with 9,406 cases in 2014. The incidence rate increased in 2015 in four states such as California, Florida, New York, and Texas. According to the CDC, Texas reported 334 cases in 2015, which was 5% more than the previous year and South Carolina witnessed around 30%-35% yearly increase over the years. The increase in incidence in the US is due to reduction or stagnant funding for prevention efforts nationwide.
In the European region, the majority are affected by MDR-TB, which comprises of 35% of the TB cases in the region. Among HBCs, 15 countries include from Central and Eastern European region. In 2013, around 532 cases of XDR-TB were reported, although it is estimated that 9% of people with MDR-TB have XDR-TB. The data estimates suggest that every year about $6.5 billion are invested toward treating TB disease.
According to a recent study, the majority of TB cases in 2015 have occurred in Asia, which accounts for about 55% of global TB cases. In China, every year, around one million new cases of TB are reported, of which around 63,000 are MDR-TB cases. The lack of healthcare infrastructure and limited access to facilities hinders the management of TB in the region.
Key players are adopting strategies such as mergers and acquisitions, partnerships, and regional expansion to stand out as strong competitors in the market. New product launches along with increased focus on R&D are another ways the leading players improve their market presence. Emergence of multiple new drugs is expected to provide a competitive edge to key players in the global women's health market.
In February 2016, Otsuka Novel Products announced global access for delamanid, an anti MDR-TB drug, to more than 100 countries through Global Drug Facility (GDF).
In August 2016, Sandoz received approval from US FDA for Erelzi, which is used to treat multiple inflammatory diseases along with TB
In March 2015, Lupin collaborated with Rotary Club, Mumbai, India, for an anti-TB campaign to create awareness, detect, and combat TB among the low-income population